Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ANV419 |
Trade Name | |
Synonyms | ANV 419|ANV-419 |
Drug Descriptions |
ANV419 is a fusion protein comprised of the cytokine IL-2 and an antibody that blocks the CD25 binding site of IL-2, which retains binding to CD122 and may lead to increased proliferation of CD8 T cells and NK cells and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2021;9). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C180674 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ANV419 | ANV419 | 0 | 3 |
ANV419 + Daratumumab | ANV419 Daratumumab | 0 | 1 |
ANV419 + Dexamethasone + Lenalidomide | ANV419 Dexamethasone Lenalidomide | 0 | 1 |
ANV419 + Ipilimumab | ANV419 Ipilimumab | 0 | 1 |
ANV419 + Nivolumab | ANV419 Nivolumab | 0 | 0 |
ANV419 + Pembrolizumab | ANV419 Pembrolizumab | 0 | 1 |
ANV419 + tumor infiltrating lymphocytes | ANV419 tumor infiltrating lymphocytes | 0 | 1 |